Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin for extensive disease small cell lung cancer

Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin for extensive disease small cell lung cancer - Randomized phase II of CBDCA+CPT vs CBDCA+AMR for ED-SCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002615

Enrollment

Registered

2009-11-01

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extensive disease small cell lung cancer

Interventions

carboplatin + irinotecan carboplatin + amrubicin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cytologically or histologically proven small cell lung caner 2. Chemotherapy-naive extensive disease small cell lung cancer 3. With performance status 0-2 4. With appropriate organ function 5. With mesurable lesion 6. With life expectancy > 2 months 7. With written informed consent

Exclusion criteria

Exclusion criteria: 1. With serirous comprications such as infection, heart disease, lung fibrosis. 2. With symptomatic brain metastasis or massive effusion 3. With active other malignancies 4. Pregnant women

Design outcomes

Primary

Measure	Time frame
Response rate	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026